Skip to content

Cancer Health Center

Font Size

Treatment Option Overview

    Wilms Tumor

    Because of the relative rarity of this tumor, all patients with Wilms tumor should be considered for entry into a clinical trial. Treatment planning by a multidisciplinary team of cancer specialists (pediatric surgeon or pediatric urologist, pediatric radiation oncologist, and pediatric oncologist) with experience treating Wilms tumor is required to determine and implement optimum treatment.

    Recommended Related to Cancer

    Treatment Option Overview

    Definitive treatment for localized and regional pheochromocytoma, including localized disease recurrence, consists of alpha- and beta-adrenergic blockade followed by surgery. For patients with unresectable or metastatic disease, treatment may include a combination of the following: Catecholamine blockade. Surgery. Chemotherapy. Radiofrequency ablation. Cryoablation. Radiation therapy. Only limited data are available from phase II clinical trials to guide the management...

    Read the Treatment Option Overview article > >

    The majority of the randomized clinical studies for treatment of children with Wilms tumor have been conducted by two large clinical groups. The National Wilms Tumor Study (NWTS) Group, which is now part of the Children's Oncology Group (COG), has established standard treatment for Wilms tumor in North America, which consists of initial surgery followed by chemotherapy and, in some patients, radiation therapy.[1,2,3] The Société Internationale d'Oncologie Pédiatrique (SIOP) is a European consortium. There are differences between the two groups that affect staging and classification. The SIOP trials provide preoperative chemotherapy before definitive resection. This statement will focus on the NWTS (now COG Renal Tumor Committee) results and studies. The major treatment conclusions of the National Wilms Tumor Studies (NWTS 1–5) are as follows:

    1. Routine, postoperative radiation therapy of the flank is not necessary for children with stage I tumors or stage II tumors with favorable histology (FH) when postnephrectomy combination chemotherapy consisting of vincristine and dactinomycin is administered.
    2. The prognosis for patients with stage III FH is best when treatment includes: (a) dactinomycin, vincristine, doxorubicin, and 10.8 Gy of radiation therapy to the flank; or (b) dactinomycin, vincristine, and 20 Gy of radiation therapy to the flank.
    3. The addition of cyclophosphamide to the combination of vincristine, dactinomycin, and doxorubicin does not improve prognosis for patients with stage IV FH tumors.
    4. A single-dose of dactinomycin per course (stages I–II FH, stage I anaplastic, stage III FH, stages III–IV, or stages I–IV clear cell sarcoma of the kidney) is equivalent to the divided-dose courses, results in the same event-free survival, achieves greater dose intensity, and is associated with less toxicity and expense.[4]
    5. Eighteen weeks of therapy is adequate for patients with stage I FH whereas other patients can be treated with 6 months of therapy instead of 15 months.[1,4,5,6,7]
    6. Tumor-specific loss of heterozygosity for combined 1p and 16q predicts recurrence of FH Wilms tumor.[8]
    7. About 2% of Wilms tumors have ureteral involvement. Presence of gross hematuria, nonfunctioning kidney, or hydronephrosis suggests the tumor may extend into the ureter and cystoscopy is recommended. En bloc resection to avoid tumor spill is recommended.[9]

      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
      Jennifer Goodman Linn self-portrait
      what is your cancer risk
      colorectal cancer treatment advances
      breast cancer overview slideshow
      prostate cancer overview
      lung cancer overview slideshow
      ovarian cancer overview slideshow
      Actor Michael Douglas